Vascular endothelial growth factor receptor-1 levels in hepatocellular carcinoma and correlations with clinicopathological features.
To determine the serum vascular endothelial growth factor receptor-1 (VEGFR-1) levels in hepatocellular carcinoma patients and its correlations with the clinical and laboratory parameters. Serum VEGFR-1 levels were measured in 18 biopsy-proven treatment-naive hepatocellular carcinoma patients (female/male: 5/13; mean age: 59.22 +/- 13.15 years) and in age- and sex-matched healthy controls. Possible associations were also evaluated between serum VEGFR-1 levels and etiology and severity of chronic liver disease, serum alpha-fetoprotein levels, presence of ascites and portal vein thrombosis, and tumor number, size and stage. Serum VEGFR-1 levels were undetectable in all healthy subjects, while all of the patients with hepatocellular carcinoma had increased VEGFR-1 (p < 0.001). Serum VEGFR-1 levels did not correlate with the clinical and laboratory parameters and tumor characteristics in hepatocellular carcinoma. VEGFR-1 is involved in the regulation of carcinogenesis in hepatocellular carcinoma.